August 31, 2009
Teikoku Seiyaku and Terumo reach basic agreement
toward comprehensive business partnership of medical narcotic drugs
in the cancer pain control domain
Teikoku Seiyaku Co., Ltd.
Terumo Corporation
Teikoku Seiyaku Co., Ltd. (Head Office: Higashikagawa City, Kagawa Prefecture; President & CEO: Shosaku Murayama; hereinafter, “Teikoku Seiyaku”) and Terumo Corporation (Head Office: Shibuya Ward, Tokyo; President: Akira Takahashi; hereinafter, “Terumo”) announced they have reached an agreement to enter into a comprehensive partnership for the development, manufacture and sale of medical narcotic drugs to alleviate the pain of cancer in the Japanese market.
Teikoku Seiyaku, a leading manufacturer of analgesic and anti-inflammatory poultices and plasters, positions “Applications of transdermal absorption technology” and “pain-relief” as their focuses of product development and has promoted such business operations as development and manufacture of narcotic drugs.
With its vision of “Terumo’s unique technology makes medical treatment kinder and gentler,” Terumo has made efforts to offer products and services from the viewpoint of patients. As part of its operations based on this vision, the company decided to fully enter the cancer pain relief domain and be a partner of Teikoku Seiyaku. Terumo also plans to strengthen its own business development toward easing the pain of patients.
Teikoku Seiyaku and Terumo will take advantage of their individual strengths, address the development and prevalence of medical narcotic drugs and put in a lot of efforts to assist patients suffering from the pain of cancer.
(Note) Forward-looking statements included in this release were determined by Teikoku Seiyaku and Terumo based on the best information available at the time of writing and are subject to potential risks and uncertainties. Therefore, please note that, due to various factors, the actual implementation may differ from what is described here.
